Kailera Therapeutics
Last verified 2026-05-02. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $900.0Mattributed |
|---|---|
| Latest round | series-b, $600.0M, 2025-10-01attributed |
| Founded | 2024 |
| Headquarters | Waltham MA |
| Industry | bio |
| Stage | series-b+ |
| Website | kailerarx.com |
Kailera Therapeutics develops next-generation GLP-1 and incretin drugs for obesity and metabolic disease, in-licensing assets from Hansoh Pharma. Patients with obesity and type 2 diabetes are the eventual customer base; clinicians and payers are buyers. Kailera advances clinical trials of KAI-9531 plus follow-on candidates with multi-receptor agonism.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-10-01 | series-b | $600.0M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series B, $600.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $900.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | kailerarx.com, read 2026-05-02 |
| Description | self-reported | kailerarx.com, read 2026-05-02 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.